By: Jason Ostedder

For decades, medical marijuana has been heralded by advocates as a versatile therapeutic tool—capable of alleviating not only physical ailments but also the burdens of mental illness. Yet a sweeping new body of research is challenging that narrative, raising serious questions about whether cannabis-based treatments can deliver on the promise many patients and policymakers have come to expect.

According to report on Friday in The New York Post, a comprehensive analysis—described by its authors as the largest review of medical cannabis to date—has found little convincing evidence that marijuana effectively treats common mental health conditions such as anxiety, depression, or post-traumatic stress disorder. The findings arrive at a moment when the use of cannabis for therapeutic purposes has become widespread, both in clinical settings and in public perception.

The study, led by Dr. Jack Wilson of the University of Sydney’s Matilda Centre for Research in Mental Health and Substance Use, examined 54 randomized controlled trials conducted over a span of more than four decades, from 1980 through 2025. These trials encompassed a wide range of conditions and formulations, including products containing cannabidiol and tetrahydrocannabinol.

Despite the breadth of the analysis, the conclusions were strikingly restrained. “In the absence of robust medical or counselling support, the use of medicinal cannabis in these cases is rarely justified,” Wilson stated, as cited by The New York Post.

The researchers reported no measurable benefit for several major psychiatric conditions, including bipolar disorder, generalized anxiety, attention-deficit hyperactivity disorder, obsessive-compulsive disorder, anorexia nervosa, and psychotic disorders. For depression—one of the most common reasons individuals seek medical cannabis—the study found a surprising absence of high-quality trials evaluating its use as a primary treatment.

These findings suggest that, while cannabis may offer subjective relief for some individuals, its efficacy as a standardized medical intervention remains unproven in many of the areas where it is most frequently promoted.

The implications of the study are particularly significant given the widespread adoption of medical cannabis across North America. As The New York Post report noted, more than 40 states, along with the District of Columbia and several US territories, have legalized cannabis for medical use over the past three decades.

Usage data further underscore its prevalence. Surveys indicate that approximately 27 percent of individuals between the ages of 16 and 65 in the United States and Canada have tried medical cannabis, with roughly half of those users turning to it specifically for mental health management.

This trend reflects both the scale of mental health challenges and the appeal of alternative treatments. In the United States alone, more than one in five adults—an estimated 59.3 million people—were living with a mental illness as of 2022. Against this backdrop, the allure of a plant-based remedy that promises relief without the side effects associated with some pharmaceutical treatments is readily understandable.

Yet the new findings suggest a troubling gap between expectation and reality. As Wilson told Reuters, “Some people may experience legitimate benefits, and that’s great. But when we look at the evidence as a whole, we just don’t see that the evidence is quite there for the routine use of these medicines.”

Beyond questions of efficacy, the study raises concerns about potential harms associated with the widespread use of medical cannabis for mental health purposes. According to The New York Post report, the researchers warned that reliance on cannabis could, in some cases, exacerbate underlying conditions or delay access to more effective treatments.

One particularly concerning finding relates to substance-use disorders. For individuals with cocaine-use disorder, the study found that cannabis use was associated with increased cravings—a development that could potentially worsen dependency rather than alleviate it.

Wilson also cautioned that the routine use of cannabis might elevate the risk of adverse outcomes, including the development of psychotic symptoms and cannabis use disorder. These risks are especially relevant in the context of mental health, where vulnerability to such complications may already be heightened.  “Though our paper didn’t specifically look at this,” Wilson noted, “the routine use of medicinal cannabis could be doing more harm than good.”

Despite its largely critical findings, the study did identify several areas in which medical cannabis shows potential. Among these are the treatment of cannabis-use disorder itself, a paradoxical but intriguing application.

Drawing a parallel to the use of methadone in treating opioid dependence, Wilson suggested that controlled cannabis formulations might help reduce harmful patterns of use when administered alongside psychological therapy. Oral cannabis products, in particular, were found to reduce smoking behavior in individuals struggling with dependency.

Additional “promising findings” were noted in conditions such as autism spectrum disorder, insomnia, and Tourette’s syndrome. In these cases, cannabis appeared to offer some symptomatic relief, including improved sleep quality and reduced severity of tics.

However, the researchers emphasized that the overall quality of evidence in these areas remains low, necessitating further investigation before definitive conclusions can be drawn.

It is important to distinguish between the study’s findings on mental health and the broader body of evidence supporting cannabis in other medical contexts. As The New York Post has reported, cannabis-based treatments have demonstrated efficacy in several well-established areas, including the management of certain types of epilepsy, the reduction of muscle spasticity in multiple sclerosis, and the alleviation of chronic pain.

These applications, supported by more robust clinical data, highlight the complexity of evaluating cannabis as a therapeutic agent. Its effectiveness appears to vary significantly depending on the condition being treated, the formulation used, and the context in which it is administered.

The study’s conclusions present a challenge for regulators and healthcare providers alike. On one hand, the widespread availability of medical cannabis reflects public demand and legislative support. On the other, the lack of strong evidence for many commonly cited uses calls into question the basis for its approval in certain contexts.

The New York Post has highlighted the need for clearer guidelines and more rigorous standards in determining when and how cannabis should be prescribed. Without such frameworks, patients may be left to navigate a complex and often confusing landscape, relying on anecdotal evidence rather than scientific consensus.

The authors of the study have called for additional research to address the gaps identified in their analysis. High-quality randomized controlled trials, they argue, are essential for establishing the safety and efficacy of cannabis-based treatments, particularly in the realm of mental health.

Such research is not without challenges. Variability in cannabis strains, dosing, and delivery methods complicates the design of standardized studies. Moreover, the evolving legal status of cannabis in different jurisdictions can influence both funding and regulatory approval for research initiatives.

The broader implications of the study extend beyond individual treatment decisions to encompass public health policy. If cannabis is widely used for conditions where its benefits are unproven, there is a risk of misallocation of resources and missed opportunities for more effective interventions.

The New York Post report underscored the importance of aligning policy with evidence, ensuring that medical practices are guided by rigorous data rather than popular perception. This alignment is particularly critical in the field of mental health, where the stakes are high and the consequences of ineffective treatment can be profound.

The image of medical marijuana as a universal remedy for mental health challenges has been deeply ingrained in public discourse. Yet the latest research suggests that this narrative may be overly optimistic, if not fundamentally flawed.

As The New York Post has consistently reported, the findings of this landmark review invite a reassessment of assumptions and a renewed commitment to evidence-based practice. While cannabis may hold promise in certain areas, its role in treating mental health disorders remains uncertain and, in many cases, unsupported by current data.

For patients, practitioners, and policymakers, the message is clear: hope must be tempered by evidence, and innovation must be guided by rigorous inquiry. In the complex and evolving landscape of mental health care, there are no shortcuts—only the careful, methodical pursuit of solutions that truly serve those in need.

Keep in mind also that  other studies have shown the exact opposite of what the University of Sydney’s Matilda Centre for Research in Mental Health and Substance Use found, and the financial backing of this study was not revealed to the public.